March 9 (Reuters) - Eli Lilly said on Monday a small number of basic Medicare drug plans may not follow the $50 per month cap ...

“The GLP-1 landscape is expected to broaden significantly,” said Dr. Christopher McGowan, a gastroenterologist who runs a weight loss clinic in Cary, North Carolina. “For the first time, medical ...

The cessation of GLP-1RAs is linked to a 60% weight regain within a year, emphasizing the importance of tailored strategies ...

TIX100 is a specific, orally available TXNIP inhibitor originally developed for its beta-cell protective effects in diabetes. It has received FDA Investigational New Drug approval in diabetes and ...

Obesity and type 2 diabetes are deeply interconnected. Yet, many diabetes prevention programs fail to adequately treat ...

Changes are coming in 2026 for GLP-1 drugs. Long defined by high prices, shortages and weekly injections, drugs including Wegovy and Zepbound are expected to be easier to access and afford. And new ...